Aaron Wenger is a senior director and principal scientist at Pacific Biosciences, where he oversees the long-read sequencing ...

Dr Aaron Wenger reveals how improvements in long-read sequencing technology is enabling the elucidation of complex disease mechanisms for targeted and effective treatments for rare diseases. Drug ...

A novel microphysiological system using ovarian follicles enables physiologically relevant three-dimensional angiogenesis ...

Insilico Medicine has nominated ISM6200, a preclinical drug candidate designed using generative AI to target NR3C1, a receptor involved in cortisol regulation.

All Opinion and interviews articles in Drug Target Review ...

A new study has revealed that age-related clonal haematopoiesis accelerates aortic aneurysm growth through RANK/RANKL signalling, meaning that repurposing osteoporosis drugs targeting this pathway ...

ELRIG is launching its first major US event, Drug Discovery USA 2026, at Pfizer’s Cambridge, Massachusetts facility on 16–17 June. The free-to-attend conference will bring together European and ...

NAMs are now part of early drug discovery, but adoption remains uneven. Join leading experts for a discussion on current applications, limitations and what is required for wider use. The session ...

The company will showcase translational research using patient-derived models and integrated molecular data across multiple cancer types and therapeutic modalities at the American Association for ...

The new platform enables researchers to analyse gene expression and cellular organisation within intact tissue at single-cell resolution, supporting large-scale studies across fresh-frozen and FFPE ...

New research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both ...

The 2025 chikungunya outbreak has surged from the Indian Ocean to Europe, prompting an urgent global research response. With no antivirals and limited vaccine access, laboratories and biotech firms ...